Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries

This article was originally published in PharmAsia News

Executive Summary

Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries
Advertisement

Related Content

As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot
As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot
AstraZeneca, Pfizer, GlaxoSmithKline: Emerging Markets Earnings Roundup (Part 2 of 2)
Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News
Rethinking Vaccine Strategy In Emerging Markets Offers Strong Growth Opportunities
Pfizer Brings Prevenar 13 To India But Lack Of Immunization Awareness Remains Concern
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
Biotech Innovation And Pharma Partnering To Address Neglected Diseases - Partnering For Global Health Forum
ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market
ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market
Advertisement
UsernamePublicRestriction

Register

SC074364

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel